Global Healthcare Analyst

Tina Banerjee

Thematic (Sector/Industry)

<ul>
<li>Daiichi Sankyo received EU approval for Enhertu in breast cancer. Kaken Pharmaceutical in-licensed hereditary angioedema drug candidate sebetralstat for Japan from KalVista Pharmaceuticals for an upfront payment of $11M.</li>
<li>ABL Bio signed £2B+ outlicensing licensing deal with GSK to develop novel medicines for neurodegenerative diseases. Samsung Biologics launched Epysqli, a biosimilar referencing Soliris in the U.S.</li>
<li>U.S. court ruled in favor of Sun Pharma regarding the launch of alopecia areata drug Leqselvi. Mayne Pharma has been involved in a legal proceeding in U.S., brought by TherapeuticsMD.</li>
</ul>


Daiichi Sankyo received EU approval for Enhertu in breast cancer. Kaken Pharmaceutical in-licensed hereditary angioedema drug candidate sebetralstat for Japan from KalVista Pharmaceuticals for an upfront payment of $11M.
ABL Bio signed £2B+ outlicensing licensing deal with GSK to develop novel medicines for neurodegenerative diseases. Samsung Biologics launched Epysqli, a biosimilar referencing Soliris in the U.S.
U.S. court ruled in favor of Sun Pharma regarding the launch of alopecia areata drug Leqselvi. Mayne Pharma has been involved in a legal proceeding in U.S., brought by TherapeuticsMD.


APAC Healthcare Weekly (April 13)- Daiichi Sankyo, Kaken, ABL Bio, Samsung Biologics, Sun Pharma

Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Market & Forensics Analyst

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

<ul>
<li>Crude oil prices dropped below $60 as OPEC+ boosted output and China retaliated with tariffs, sparking global trade and demand concerns.</li>
<li>For India, every $10/bbl fall can cut CAD by 0.5% of GDP, ease inflation by 0.3%, but risks lower fiscal revenue due to fuel tax dependence.</li>
<li>While beneficial short-term, India must prepare for volatility—by diversifying energy, insulating fiscal math, and enhancing trade resilience amidst rising geopolitical uncertainty.</li>
</ul>


Crude oil prices dropped below $60 as OPEC+ boosted output and China retaliated with tariffs, sparking global trade and demand concerns.
For India, every $10/bbl fall can cut CAD by 0.5% of GDP, ease inflation by 0.3%, but risks lower fiscal revenue due to fuel tax dependence.
While beneficial short-term, India must prepare for volatility—by diversifying energy, insulating fiscal math, and enhancing trade resilience amidst rising geopolitical uncertainty.


Crude Oil Below $ 60: OPEC’s Pivot, China’s Tariffs, and the New Oil Equation

Asia Economist, Founder, Asia Decoded

Priyanka Kishore

Asia Economist, Founder

Asia Decoded

Independent, data-centric insights that help you stay on top of Asia's economics and geopolitics.

Independent Data-centric Insights

Macroeconomics

<ul>
<li>The swift escalation in the US-China trade war would ordinarily have been a trigger for faster supply chain diversification.</li>
<li>But this is unlikely amid skyrocketing uncertainty. Investments will likely slow to a crawl over 2025-26, as firms delay decisions on expansions and relocation of production to new destinations.</li>
<li>Firms cannot move manufacturing to the US at the rapid pace at which tariffs are being implemented, without running into production bottlenecks and higher costs.</li>
</ul>


The swift escalation in the US-China trade war would ordinarily have been a trigger for faster supply chain diversification.
But this is unlikely amid skyrocketing uncertainty. Investments will likely slow to a crawl over 2025-26, as firms delay decisions on expansions and relocation of production to new destinations.
Firms cannot move manufacturing to the US at the rapid pace at which tariffs are being implemented, without running into production bottlenecks and higher costs.


'China Plus' Is Collateral Damage of 'America First'

CEO, A. Stotz Investment Research

Dr. Andrew Stotz, CFA

Quantamental Investing to beat Benchmarks

A. Stotz Investment Research

We pick stocks. We construct portfolios. All our effort is focused on how to better pick stocks and construct portfolios. We serve fund management companies, family offices, and high net worth individuals.

<ul>
<li>We highlight 14 stocks in Asia that look interesting to us based on our FVMR methodology</li>
<li>Portfolio changes: Two stock remains, 12 stocks added into portfolio</li>
<li>Since its inception, it has generated a before-fee total return of 200% versus the MSCI Asia ex Japan of 77%</li>
</ul>


We highlight 14 stocks in Asia that look interesting to us based on our FVMR methodology
Portfolio changes: Two stock remains, 12 stocks added into portfolio
Since its inception, it has generated a before-fee total return of 200% versus the MSCI Asia ex Japan of 77%


HarmoniQ Insights

William Mann

Independent Insight Provider

At HarmoniQ Insights, we empower investors to enhance their investment strategies by integrating cutting-edge quantitative research processes and technologies. Our solutions provide access to leading quantitative data providers and services, tailored to align with each client’s unique goals. By bridging the gap between traditional investment approaches and advanced data-driven methods, we help clients gain a competitive edge through innovation in both process and technology.

Cross Asset Strategy

<ul>
<li>A fascinating lunch discussion with LLM engineer sparked an investigation into how AI models process information through vector spaces - revealing parallel but mechanistically different biases compared to human analysts </li>
<li>Built comprehensive framework mapping traditional financial biases against their LLM counterparts - showing how things like confirmation bias manifest differently (emotional investment vs statistical pattern reinforcement)</li>
<li>Result: Effective quant research requires understanding both human AND machine biases - can't just apply traditional risk controls to LLMs. Need tailored mitigations for how biases uniquely manifest in #AI.  </li>
</ul>


A fascinating lunch discussion with LLM engineer sparked an investigation into how AI models process information through vector spaces - revealing parallel but mechanistically different biases compared to human analysts 
Built comprehensive framework mapping traditional financial biases against their LLM counterparts - showing how things like confirmation bias manifest differently (emotional investment vs statistical pattern reinforcement)
Result: Effective quant research requires understanding both human AND machine biases - can't just apply traditional risk controls to LLMs. Need tailored mitigations for how biases uniquely manifest in #AI.  


Understanding LLM Biases in Quantitative Research: From Lunch Conversation to Framework

Bangladesh
Insights on Bangladesh

APAC Healthcare Weekly (April 13)- Daiichi Sankyo, Kaken, ABL Bio, Samsung Biologics, Sun Pharma

Daiichi got EU approval for Enhertu. Kaken Pharma signed inlicensing deal, while ABL stuck outlicensing deal. Sun Pharma's Leqselvi is now free to...

Tina Banerjee

Crude Oil Below $ 60: OPEC’s Pivot, China’s Tariffs, and the New Oil Equation

Crude oil price drop below $60 impacts global trade and demand; India benefits short-term but must prepare for volatility by diversifying energy...

Nimish Maheshwari

'China Plus' Is Collateral Damage of 'America First'

Trump tariffs are unlikely to give a strong immediate push to supply chain diversification. We expect the impact to be quite the opposite amid...

Priyanka Kishore

The Stocks to Own in Asia – Vol. 48

We highlight 14 stocks in Asia that look interesting to us based on our FVMR methodology. Since its inception, it has generated a before-fee total...

A. Stotz Investment Research

Understanding LLM Biases in Quantitative Research: From Lunch Conversation to Framework

We are going to provide a full-blown update on LLMs through Q1 2025. In the meantime, we are still finding issues with 🤖 “Hallucinating on Drugs” –...

William Mann

APAC Healthcare Weekly (April 13)- Daiichi Sankyo, Kaken, ABL Bio, Samsung Biologics, Sun Pharma

Daiichi got EU approval for Enhertu. Kaken Pharma signed inlicensing deal, while ABL stuck outlicensing deal. Sun Pharma's Leqselvi is now free to...

Tina Banerjee

Crude Oil Below $ 60: OPEC’s Pivot, China’s Tariffs, and the New Oil Equation

​Crude oil price drop below $60 impacts global trade and demand; India benefits short-term but must prepare for volatility by diversifying energy...

Nimish Maheshwari

'China Plus' Is Collateral Damage of 'America First'

Trump tariffs are unlikely to give a strong immediate push to supply chain diversification. We expect the impact to be quite the opposite amid...

Priyanka Kishore

The Stocks to Own in Asia – Vol. 48

We highlight 14 stocks in Asia that look interesting to us based on our FVMR methodology. Since its inception, it has generated a before-fee total...

A. Stotz Investment Research

Understanding LLM Biases in Quantitative Research: From Lunch Conversation to Framework

We are going to provide a full-blown update on LLMs through Q1 2025. In the meantime, we are still finding issues with 🤖 “Hallucinating on Drugs” –...

William Mann

Crude oil price drop below $60 impacts global trade and demand; India benefits short-term but must prepare for volatility by diversifying energy...